Results 51 to 60 of about 226,969 (309)

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. [PDF]

, 2014
BackgroundIn the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone ...
Baselga, J, Bauly, H, Burris, HA, Chouinard, E, Csoszi, T, Eakle, J, El-Hashimy, M, Feng, W, Geberth, M, Gnant, M, Hortobagyi, G, Noguchi, S, Perez, A, Piccart, M, Pritchard, KI, Puttawibul, P, Rugo, HS, Srimuninnimit, V, Taran, T   +18 more
core   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Factors influencing COVID-19 vaccine breakthrough infections: an analysis of healthcare workers in Ardabil, Iran [PDF]

Health Science Monitor
Background & Aims: Investigating re-infection with COVID-19 is necessary due to the existence of genetic differences among populations after a general vaccination plan. In addition to genetic differences, gender, age, the presence of underlying diseases,
Elham Rezaei, Shafagh Aliasgarzadeh, Sevda Mikaeili mirak, Faraz Tayyar-Iravanlou   +3 more
doaj  

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. [PDF]

, 2016
Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck ...
Berger, Raanan, Burtness, Barbara, Cheng, Jonathan D, Chow, Laura QM, Chung, Hyun Cheol, Dolled-Filhart, Marisa, Eder, Joseph Paul, Geva, Ravit, Gupta, Shilpa, Haddad, Robert, Kang, Hyunseok, Keam, Bhumsuk, Lee, Se-Hoon, Lin, Chia-Chi, Mahipal, Amit, Mehra, Ranee, Meister, Amy, Muro, Kei, Pathiraja, Kumudu, Seiwert, Tanguy Y, Tahara, Makoto, Weiss, Jared   +21 more
core   +2 more sources

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Die Medizin der Zukunft braucht ein modernes AMNOG

Monitor Versorgungsforschung
Im Koalitionsvertrag steht: „Wir werden Deutschland zum weltweit innovativsten Chemie-, Pharma- und Biotechnologiestandort machen.“ Das ist eine kluge Entscheidung.
Alexandra Bishop
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Assessment of Some Immunological Parameters Postvaccination with Different Types of COVID-19 Vaccines

Medical Journal of Babylon
Background: Coronavirus disease 2019 (COVID-19) is a highly contagious viral infection that can spread rapidly worldwide. Several vaccines have been developed to combat COVID-19.
Haneen Saad Khasbak, Hayder Shkhair Al-Janabi, Mohanad Jawad Kadhim   +2 more
doaj   +1 more source

Evaluation of the effectiveness and adverse effects of COVID-19 vaccines administered at Kashan University of Medical Sciences [PDF]

International Archives of Health Sciences
Objectives: The development of protective immunity through COVID-19 vaccines is influenced by both host factors and the composition of the vaccine. Therefore, it is essential to assess the efficacy and side effects of different vaccines among individuals
Zahra Soleimani, Kamal Esalatmanesh, Mohammad Mehdi Safaaddin Kashani, Mohamadjavad Azadchehr, Roozbeh Esalatmanesh   +4 more
doaj   +1 more source